March 14, 2024 Improving Data Collection for Rare Epilepsies: Case example from the TSC Natural History Presented by Elizabeth Cassidy, MPH from TSC Alliance...
March 8, 2024 Rare Neurodegenerative Disease Efforts Under the ACT for ALS In this webinar from The Critical Path Institute’s Rare and Orphan Disease Program CP-RND consortium, members discuss...
March 5, 2024 C-Path Wraps Up Productive Leadership Retreat, In-Person Meetings Critical Path Institute proudly recruits elite talent from across the globe, supporting remote work and a healthy work-life....
February 15, 2024 C-Path Launches Revamped Website to Enhance Collaborations in Drug Development Critical Path Institute (C-Path) today officially launched its newly revamped website, designed to further enhance collab...
February 15, 2024 Understanding Disease Progression Models: What are They, Why are They Useful, & How Are They Applied Disease progression modeling synthesizes statistics with disease knowledge and data to inform predictions and understanding of dis
February 8, 2024 TRxA 2024 Funding Opportunities Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) is proud to announce its 2024 global...
February 7, 2024 Dr. Janet Woodcock: A Visionary Leader in Regulatory Science and the Inspirational Force behind the Creation of Critical Path Institute In her nearly four decades with the U.S. Food and Drug Administration, Dr. Janet Woodcock personally transformed the culture of...
February 1, 2024 FamilieSCN2A Partners with C-Path’s RDCA-DAP, Advancing Research Efforts for SCN2A-Related Disorders n a significant step to enhance research efforts for SCN2A-related autism and epilepsy, Critical Path Institute (C-Path) and Famil
February 1, 2024 A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research Parkinson's disease and dementia with Lewy bodies are currently defined by their clinical features, with α-synuclein pathology...
January 30, 2024 TRxA 2024 Funding Opportunities TRxA’s focus is translating early-stage novel therapeutics into Investigational New Drug (IND) supporting data packages that...
